FDC Limited (FDC) — Announcement | 13 August 2026

· NSE Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
Subsidiary secures UK marketing authorization for Atropine eye drops

FDC Limited announced that its subsidiary FDC International Limited received marketing authorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for Atropine 1.0% w/v Eye Drops Solution, enabling sales in the UK market.

📄 View Original Announcement (PDF)

About FDC Limited (FDC)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹5,534.73 Cr P/E: 18.9 ROE: 12.8% ROCE: 17.3% Div Yield: 1.47%

View full FDC stock details →

📡 Get AI alerts when FDC files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track FDC — Free

📊 More FDC filings

See all FDC filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when FDC files new disclosures

Track FDC filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track FDC — Free

Free account · 2 AI queries/day